

# CIPLA LIMITED

# January 27, 2016

	BSE Code:	500087	NSE Code:	CIPLA	Reuters Code:	CIPL.NS	Bloomberg Code:	CIPLA:IN	
				м	arket Data				
			-		cal companies with any has 180 global C	MP (Rs.)		5	581
	partners ac	ross 120 countrie	es. Cipla has a j	presence in A	frica, Middle East, Fa	ace Value			2.0
	Latin Ameri	ca, Asia Pacific,	China and Russ	ia. In the dor	nestic market, the 52	2 week H/L (Rs.)		753/	/571
company is a prominent player with a gamut of product offerings and a			ct offerings and a Ad	dj. all time High (Rs.)			753		
		vork of 7,500 MRs.				ecline from 52WH (%)		2	22.9
network		500 MIAS.			Ri	se from 52WL (%)			1.6
		velopments			Be	eta			0.7
	Key Deve				Μ	lkt. Cap (Rs.Cr)		46,	,628
				Fr	nterprise Value(Rs) Cr	)	50	614	

#### S **Key inhalation launches in Europe:**

The company has started the launch of inhalers in Europe. Cipla had already launched gSeretide in certain EU (non-UK) territories. It has over 200 drugs under development.

#### S US acquisitions – InvaGen and Exelan:

Cipla (EU) Ltd. has entered into an agreement to acquire two US based companies viz. - InvaGen Pharmaceuticals and Exelan Pharmaceuticals Inc. InvaGen currently has 40 approved ANDAs (Abbreviated New drug Application) (32 commercialized) and a pipeline of 30 pending ANDAs (including 5 FTFs (first to file)). After the acquisition, the company's ANDAs pending for approval with the USFDA (US Food & Drug Administration) stands at more than 100 with key complex generics in InvaGen portfolio.

#### S **Domestic business performance:**

Cipla is one of the major players in the domestic formulation market and Indian business contributes 43% to the company's overall revenues with 5.27% market share in branded generics and key therapies such as respiratory and anti-viral. During FY15, the company posted a growth of 20% and the company launched the generic drug of sofosbuvir for the treatment of hepatitis-C.

#### S International (Rest of the World) operations:

International markets include all export markets excluding North America, South Africa and Europe with 180 global partners across 120 countries. Cipla has presence in Africa, Middle East, Latin America, China and Russia. International business contributed 25% to the top line in FY15 registering a growth of 9%.

Market Data				
CMP (Rs.)	581			
Face Value	2.0			
52 week H/L (Rs.)	753/571			
Adj. all time High (Rs.)	753			
Decline from 52WH (%)	22.9			
Rise from 52WL (%)	1.6			
Beta	0.7			
Mkt. Cap (Rs.Cr)	46,628			
Enterprise Value(Rs. Cr)	50,614			

#### **Fiscal Year Ended (Standalone)**

	FY13	FY14	FY15
Total revenue (Rs.cr)	8,279	10,173	11,345
Net Profit (Rs.cr)	1,545	1,388	1,181
Share Capital (Rs.Cr)	161	161	161
EPS (Rs.)	18.1	15.5	14.7
P/E (x)	21.0	24.7	51.4
P/BV (x)	3.4	3.0	5.2
ROE (%)	17.4	13.0	10.5




Shareholding	Sep15	Jun15	Diff.
Promoters	36.8	36.8	0.0
DII	11.7	16.0	(4.3)
FII	22.5	18.3	4.2
Others	29.0	28.9	0.1



Cipla is a major manufacturer of pMDIs (Metered dose inhalers) in the world.

# Cipla Ltd: Business Overview

Cipla Ltd. offers a wide range of products in top therapies including respiratory, anti-infectives, cardiac, gastroenterology and urology. The company has 34 manufacturing facilities in different locations. Cipla derives 57% of its total revenue from exports and 43% from domestic business. The formulations business accounts for 93% and APIs account for the remaining 7% of the total revenue. In the domestic market, chronic and acute therapies contribute 53% and 47% respectively. Cipla is one of the prominent manufacturers of pMDIs (Metered dose inhalers) in the world with a broad-based portfolio of inhalation products including more than 27 molecules across a range of devices.






Indian business contributes 43% to Cipla's revenues with 5.27% market share in branded generics and key therapies such as respiratory and anti-viral.

Cipla (EU) Ltd. has entered into an agreement to acquire two US based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals Inc.

# **Domestic business of Cipla**

Cipla is one of the key players in the domestic formulation market and its Indian business contributes 43% to overall revenues with 5.27% market share in branded generics with key therapies such as respiratory and anti-viral. During FY15, the company posted a growth of 20% compared to industry growth of 12% and the company launched the generic drug of sofosbuvir for the treatment of hepatitis-C.

Cipla is among the few innovators for inhalation therapy in India and its respiratory products are available in over 100 countries with largest portfolio of products to suit individual patient needs. The company's respiratory business is around USD 300-350 mn p.a. During H1FY16, the company reported a muted growth of 5% in domestic business.



# Cipla gains scale in the US generics market through InvaGen acquisition

North America contributed 8% of total revenue in FY15 with a growth of 20% YoY. The company has transformed its business model from partner based to own front end during past two years. In the US, Cipla has a robust product pipeline of 147 ANDAs, out of which, 79 are approved.

Cipla (EU) Ltd. has entered into an agreement to acquire two US based companies, InvaGen Pharmaceuticals and Exelan Pharmaceuticals Inc. Invagen was incorporated in the year 2003 and is engaged in the business of development, manufacturing, marketing and distribution of generic pharmaceuticals with focus on a wide range of therapeutic areas including cardiovascular, anti-infective, CNS, anti-inflammatory, anti-diabetic and anti-depressants. Exelan was incorporated in the year 2011 and is engaged in the business of sales and marketing of generic pharmaceuticals for the government and institutional markets.

InvaGen currently has 40 approved ANDAs (32 commercialized) and a pipeline of 30 pending ANDAs (including 5 FTFs). After the acquisition, the company's ANDAs pending for approval with the USFDA stand at more than 100 with key complex generics in InvaGen portfolio.

Acquired Companies revenue trend						
Revenue (USD mn)	CY12	CY13	CY14	CAGR CY12-14		
InvaGen	130	135	190	21%		
Exelan	2	14	28	274%		
Total	132	149	218	29%		



Cipla is one of the major pharmaceutical companies in South Africa with a market share of more than 5% and it contributes 14% to the total revenues.

International business contributed 25% to the company's top-line in FY15 growing by 9%.

During FY15, the company has added more than 70 new products to the pipeline.

## South Africa: Robust private business

Cipla is one of the prominent pharmaceutical companies in South Africa with market share of more than 5% and it contributes 14% to the total revenues. South African business revenue has grown at 9%p.a. in the private market (Medpro's 73% of revenues) over the last 3 years. The manufacturing facility in Durban generated a profit in FY15 as compared to a loss in FY14. Further during FY15, Medpro Pharmaceuticals Pvt. Ltd (Subsidiary of Cipla Medpro) entered into sales and distribution agreement with Teva Pharmaceuticals Ltd. to focus on the oncology, central nervous system, women's health, cardiovascular and other specialty therapies.

### Europe: gSeretide MDI launch

Europe (20 countries) accounts for 4% of revenues and posted a de-growth of 24% in FY15 driven by one-off event (supply related issue). Further, the company has launched combination inhalers in Europe. Moreover, Cipla is focused on adding innovative elements to its products and currently it has more than seven different inhaler products in a single market.

## International (Rest of the World) business operations


International markets include all export markets excluding North America, South Africa and Europe with 180 global partners across 120 countries. Cipla has presence in Africa, Middle East, Latin America, China and Russia. International business contributed 25% to the top-line in FY15 growing by 9%. The company changed its business model in a few regions and adopted direct- to-market approach.

## APIs business revenues declining due to rise in captive consumption

Cipla manufactures APIs (Active Pharmaceutical Ingredients) for more than 300 partners globally with major contribution from the ARVs, gastroenterology, respiratory, neurology and oncology segments. During FY15, the company has added more than 70 new products to the pipeline expanding reach across key therapies. APIs revenue contributed 7% to total revenues in FY15 and posted de-growth of 18%.

## R&D spend on the rise

The company has expanded applications across multiple technology platforms including implants, microspheres, nanotechnology, preservative free ophthalmic and nasal sprays. Currently,Cipla has more than 200 formulation projects in development which indicates a sturdy pipeline.





#### **Balance Sheet (Consolidated)**

(Rs.Cr)	FY13	FY14	FY15
Share Capital	161	161	161
Reserve and surplus	8,858	9,890	10,641
Net Worth	9,019	10,050	10,801
Minority Interest	0	50	180
Total Debt	967	1,228	1,702
Other non-current liabilities	361	419	486
Total Equity & Liabilities	10,347	11,747	13,169
Fixed Assets	3,988	4,445	4,852
Investments	2,532	3,202	3,198
Net current assets	3,356	3,687	4,700
Other non-current assets	470	413	419
Total Assets	10,347	11,747	13,169

#### Profit & Loss Account (Consolidated)

(Rs.Cr)	FY13	FY14	FY15
Net revenue	8,279	10,173	11,345
Expenses	6,042	8,040	9,184
EBITDA	2,238	2,133	2,162
Depreciation	330	373	505
EBIT	1,907	1,760	1,657
Interest cost	34	146	168
Other Income	128	123	96
Profit Before Tax	2,001	1,738	1,585
Tax	544	463	400
Profit After Tax	1,457	1,274	1,185
Minority Interests	0	16	48
P/L from Associates	(6)	(12)	(25)
Adjusted PAT	1,451	1,246	1,112
E/o income / (Expense)	94	142	69
Net Profit	1,545	1,388	1,181

#### Cash Flow (Consolidated)

Y/E (Rs. Cr)	FY13	FY14	FY15
Net profit/loss before tax& extraordinary items	2,095	1,880	1,654
Net cashflow from operating activities	1,438	(930)	917
Net cash used in investing activities	(2,136)	1,244	(685)
Net cash used from financing activities	751	(266)	165
Net inc/dec in cash and cash equivalents	53	48	397

### Key Ratios (Consolidated)

	FY13	FY14	FY15
EBITDA Margin (%)	27.0	21.0	19.1
EBIT Margin (%)	24.6	18.5	15.5
NPM (%)	17.5	12.2	9.8
ROCE (%)	23.1	17.7	14.6
ROE (%)	17.4	13.0	10.5
EPS (Rs.)	18.1	15.5	14.7
P/E (x)	21.0	24.7	51.4
BVPS(Rs.)	112.3	125.2	134.5
P/BVPS (x)	3.4	3.0	5.2
EV/EBITDA (x)	13.9	14.9	27.0

#### Financial performance snapshot

Net sales of the company stood at Rs. 11,345 Crores in FY15, a growth of 11.5% as compared to Rs. 10,173 Crores in FY14. The operating expenses of the company increased by 14.2% YoY to Rs. 9,184 Crores from Rs. 8,040 Crores during the year. The company's EBITDA grew by 1.3% YoY to Rs. 2,162 Crores in FY15 from Rs. 2,133 Crores in FY14. EBITDA margin contracted by 191 bps to 19.1% in FY15 from 21.0% in FY14. Net profit witnessed a decline of 15.0% to Rs. 1,181 Crores in FY15 from Rs. 1,388 Crores in FY14. The net profit margin contracted by 245 bps to 9.8% from 12.2% during the above period.





Indbank Merchant Banking Services Ltd. I Floor, Khiviraj Complex I, No.480, Anna Salai, Nandanam, Chennai 600035 Telephone No: 044 – 24313094 - 97 Fax No: 044 – 24313093 www.indbankonline.com

#### Disclaimer

#### @ All Rights Reserved

This report and Information contained in this report is solely for information purpose and may not be used as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. The investment as mentioned and opinions expressed in this report may not be suitable for all investors. In rendering this information, we assumed and relied upon, without independent verification, the accuracy and completeness of all information that was publicly available to us. The information has been obtained from the sources that we believe to be reliable as to the accuracy or completeness. While every effort is made to ensure the accuracy and completeness of information. This information is given in good faith and we make no representations or warranties, express or implied as to the accuracy or completeness of the informations or warranties, express or implied as to the accuracy or completeness of the information. No one can use the information as the basis for any claim, demand or cause of action.

Indbank and its affiliates shall not be liable for any direct or indirect losses or damage of any kind arising from the use thereof. Opinion expressed is our current opinion as of the date appearing in this report only and are subject to change without any notice.

Recipients of this report must make their own investment decisions, based on their own investment objectives, financial positions and needs of the specific recipient. The recipient should independently evaluate the investment risks and should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult their advisors to determine the merits and risks of such investment.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and is not meant for public distribution. This document should not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced, duplicated or sold in any form.